Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis

Iain B McInnes, Peter Nash, Christopher Ritchlin, Ernest Choy, Steve Kantars, Howard Thom, Kunal Ghandhi, Luminita Pricop, Steffen M Jugl

Research output: Contribution to journalArticle (Academic Journal)peer-review

15 Citations (Scopus)
259 Downloads (Pure)

Abstract

Aim: A network meta-analysis (NMA) using randomized controlled trial data compared psoriatic arthritis (PsA) outcomes (ACR, PASI and PsARC response rates) at 12–16 weeks for secukinumab, adalimumab, apremilast, certolizumab, etanercept, golimumab, infliximab, and ustekinumab. Patients & methods: Trials were identified by systematic review. Separate networks were developed for the full study populations, biologic-naïve patients, and biologic-experienced patients. Results: In the full populations, secukinumab, adalimumab, golimumab and infliximab demonstrated the highest ACR response rates. Secukinumab and infliximab demonstrated the highest PASI response rates, and infliximab and etanercept demonstrated the highest PsARC response rates. Conclusion: In the full populations, secukinumab demonstrated good efficacy across all outcomes. All treatments for active PsA included in this comprehensive NMA demonstrated superiority to placebo.
Original languageEnglish
Number of pages18
JournalJournal of Comparative Effectiveness Research
Early online date19 Sep 2018
DOIs
Publication statusE-pub ahead of print - 19 Sep 2018

Fingerprint Dive into the research topics of 'Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis'. Together they form a unique fingerprint.

Cite this